171 related articles for article (PubMed ID: 38627904)
1. Evaluate the in vitro effect of anthracycline and alkylating cytophosphane chemotherapeutics on dopaminergic neurons.
Desai D; Majrashi M; Pathak S; Almaghrabi M; Liu K; Pondugula SR; Tiwari AK; Babu RJ; Deruiter J; Dhanasekaran M
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2074. PubMed ID: 38627904
[TBL] [Abstract][Full Text] [Related]
2. Sequencing of anthracyclines and taxanes in neoadjuvant and adjuvant therapy for early breast cancer.
Zaheed M; Wilcken N; Willson ML; O'Connell DL; Goodwin A
Cochrane Database Syst Rev; 2019 Feb; 2(2):CD012873. PubMed ID: 30776132
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin-induced neurotoxicity is associated with acute alterations in synaptic plasticity, apoptosis, and lipid peroxidation.
Alhowail AH; Bloemer J; Majrashi M; Pinky PD; Bhattacharya S; Yongli Z; Bhattacharya D; Eggert M; Woodie L; Buabeid MA; Johnson N; Broadwater A; Smith B; Dhanasekaran M; Arnold RD; Suppiramaniam V
Toxicol Mech Methods; 2019 Jul; 29(6):457-466. PubMed ID: 31010378
[TBL] [Abstract][Full Text] [Related]
4. Cardioprotective Effects of Oroxylum indicum Extract Against Doxorubicin and Cyclophosphamide-Induced Cardiotoxicity.
Pondugula SR; Harshan A; Ramesh S; Govindarajulu M; Almaghrabi M; Majrashi M; Abbott KL; Nadar R; Alturki M; Salamat JM; Smith F; Majeed M; Nagabhushanam K; Moore T; Ren J; Dhanasekaran M
Cardiovasc Toxicol; 2022 Jan; 22(1):67-77. PubMed ID: 34623620
[TBL] [Abstract][Full Text] [Related]
5. The triangle of death of neurons: Oxidative damage, mitochondrial dysfunction, and loss of choline-containing biomolecules in brains of mice treated with doxorubicin. Advanced insights into mechanisms of chemotherapy induced cognitive impairment ("chemobrain") involving TNF-α.
Ren X; Keeney JTR; Miriyala S; Noel T; Powell DK; Chaiswing L; Bondada S; St Clair DK; Butterfield DA
Free Radic Biol Med; 2019 Apr; 134():1-8. PubMed ID: 30593843
[TBL] [Abstract][Full Text] [Related]
6. Neural correlates in functional brain mapping among breast cancer survivors receiving different chemotherapy regimens: a qEEG/HEG-based investigation.
Vasaghi Gharamaleki M; Mousavi SZ; Owrangi M; Gholamzadeh MJ; Kamali AM; Dehghani M; Chakrabarti P; Nami M
Jpn J Clin Oncol; 2022 Nov; 52(11):1253-1264. PubMed ID: 35946328
[TBL] [Abstract][Full Text] [Related]
7. Arterial Stiffness Use for Early Monitoring of Cardiovascular Adverse Events due to Anthracycline Chemotherapy in Breast Cancer Patients. A Pilot Study.
Souza CA; Simões R; Borges KBG; Oliveira AN; Zogeib JB; Alves B; Malachias MVB; Drummond-Lage AP; Rezende BA
Arq Bras Cardiol; 2018 Nov; 111(5):721-728. PubMed ID: 30281690
[TBL] [Abstract][Full Text] [Related]
8. Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy.
Yonemori K; Katsumata N; Kaneko M; Uno H; Matsumoto K; Kouno T; Shimizu C; Ando M; Takeuchi M; Fujiwara Y
Breast Cancer Res Treat; 2007 Jul; 103(3):313-8. PubMed ID: 17063267
[TBL] [Abstract][Full Text] [Related]
9. Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers.
Lehmann-Che J; André F; Desmedt C; Mazouni C; Giacchetti S; Turpin E; Espié M; Plassa LF; Marty M; Bertheau P; Sotiriou C; Piccart M; Symmans WF; Pusztai L; de Thé H
Oncologist; 2010; 15(3):246-52. PubMed ID: 20228131
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of lecithinized human recombinant super oxide dismutase as cardioprotectant in anthracycline-treated breast cancer patients.
Broeyer FJ; Osanto S; Suzuki J; de Jongh F; van Slooten H; Tanis BC; Bruning T; Bax JJ; Ritsema van Eck HJ; de Kam ML; Cohen AF; Mituzhima Y; Burggraaf J
Br J Clin Pharmacol; 2014 Nov; 78(5):950-60. PubMed ID: 24844787
[TBL] [Abstract][Full Text] [Related]
11. Rutin protects against neuronal damage in vitro and ameliorates doxorubicin-induced memory deficits in vivo in Wistar rats.
Ramalingayya GV; Cheruku SP; Nayak PG; Kishore A; Shenoy R; Rao CM; Krishnadas N
Drug Des Devel Ther; 2017; 11():1011-1026. PubMed ID: 28408800
[TBL] [Abstract][Full Text] [Related]
12. Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.
Mackey JR; Pieńkowski T; Crown J; Sadeghi S; Martin M; Chan A; Saleh M; Sehdev S; Provencher L; Semiglazov V; Press MF; Sauter G; Lindsay M; Houé V; Buyse M; Drevot P; Hitier S; Bensfia S; Eiermann W
Ann Oncol; 2016 Jun; 27(6):1041-1047. PubMed ID: 26940688
[TBL] [Abstract][Full Text] [Related]
13. Enhanced therapeutic efficacy of doxorubicin/cyclophosphamide in combination with pitavastatin or simvastatin against breast cancer cells.
Dewidar SA; Hamdy O; Soliman MM; El Gayar AM; El-Mesery M
Med Oncol; 2023 Dec; 41(1):7. PubMed ID: 38051378
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant dose-dense doxorubicin-cyclophosphamide versus docetaxel-doxorubicin-cyclophosphamide for high-risk breast cancer: First results of the randomised MATADOR trial (BOOG 2004-04).
van Rossum AGJ; Kok M; van Werkhoven E; Opdam M; Mandjes IAM; van Leeuwen-Stok AE; van Tinteren H; Imholz ALT; Portielje JEA; Bos MMEM; van Bochove A; Wesseling J; Rutgers EJ; Linn SC; Oosterkamp HM;
Eur J Cancer; 2018 Oct; 102():40-48. PubMed ID: 30125761
[TBL] [Abstract][Full Text] [Related]
15. Cognitive impairment and elevated peripheral cytokines in breast cancer patients receiving chemotherapy.
Khan MA; Bhurani D; Hoda U; Sehar N; Agarwal N
Arq Neuropsiquiatr; 2022 Aug; 80(8):786-793. PubMed ID: 36252586
[TBL] [Abstract][Full Text] [Related]
16. Sequential adjuvant therapy with doxorubicin/paclitaxel/cyclophosphamide for resectable breast cancer involving four or more axillary nodes.
Hudis CA; Seidman AD; Baselga J; Raptis G; Lebwohl D; Gilewski T; Currie V; Moynahan ME; Sklarin N; Fennelly D
Semin Oncol; 1995 Dec; 22(6 Suppl 15):18-23. PubMed ID: 8643965
[TBL] [Abstract][Full Text] [Related]
17. Phase II clinical and pharmacological study of pirarubicin in combination with 5-fluorouracil and cyclophosphamide in metastatic breast cancer.
Dhingra K; Frye D; Newman RA; Walters R; Theriault R; Fraschini G; Smith T; Buzdar A; Hortobagyi GN
Clin Cancer Res; 1995 Jul; 1(7):691-7. PubMed ID: 9816034
[TBL] [Abstract][Full Text] [Related]
18. Dose-dense anthracycline-based chemotherapy for node-positive breast cancer.
Ellis GK; Livingston RB; Gralow JR; Green SJ; Thompson T
J Clin Oncol; 2002 Sep; 20(17):3637-43. PubMed ID: 12202664
[TBL] [Abstract][Full Text] [Related]
19. Doxorubicin and cisplatin induced cognitive impairment: The possible mechanisms and interventions.
Ongnok B; Chattipakorn N; Chattipakorn SC
Exp Neurol; 2020 Feb; 324():113118. PubMed ID: 31756316
[TBL] [Abstract][Full Text] [Related]
20. Phase IIIb Safety and Efficacy of Intravenous NEPA for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients with Breast Cancer Receiving Initial and Repeat Cycles of Anthracycline and Cyclophosphamide (AC) Chemotherapy.
Schwartzberg L; Navari R; Clark-Snow R; Arkania E; Radyukova I; Patel K; Voisin D; Rizzi G; Wickham R; Gralla RJ; Aapro M; Roeland E
Oncologist; 2020 Mar; 25(3):e589-e597. PubMed ID: 32162813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
